Vertex Pharmaceuticals Incorporated (NASDAQ ... and is pioneering treatments for T1D, including VX-880, a stem cell-derived therapy aimed at restoring insulin production. Clinical trials have ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...

Three people with type 1 diabetes who received Vertex Pharma’s islet cell therapy VX-880 have been able to come off insulin altogether within a year, raising the prospect of a life without ...

with VX-880 and VX-264, represent a potentially transformative approach to a chronic condition affecting millions worldwide. Furthermore, Vertex's pipeline includes promising candidates for AMKD ...

The current data for VX-880, as you know, which is in pivotal development ... the device was invented by our team was at Semma, now Vertex that are still all there as the device has novel ...

Vertex is also evaluating VX-880 in a phase 3 study as a potential cure for severe type 1 diabetes. Fourth, I expect Vertex will likely further expand its pipeline through business development deals.

Vertex Pharmaceuticals Incorporated ... treatment of APOL1-mediated kidney disease which is in single Phase 2; VX-880 and VX-264, treatment for Type 1 Diabetes; VX-670 for the treatment of ...

Vertex is also evaluating VX-880 in a phase 3 study as a potential cure for severe type 1 diabetes. Fourth, I expect Vertex will likely further expand its pipeline through business development deals.